Last updated: February 21, 2026
What is NDC 00069-0335?
NDC 00069-0335 refers to a specific formulation of Amphotericin B (liposomal), a broad-spectrum antifungal agent used primarily in severe fungal infections and associated with higher-cost treatments in hospital settings.
Market Overview
Indications and Usage
Liposomal Amphotericin B is indicated for invasive fungal infections such as Aspergillosis, Cryptococcosis, and Candida infections, especially in immunocompromised patients. Its use has increased with rising cases of immunosuppressed populations, including oncology, transplant, and AIDS patients.
Market Size and Trends
- The global antifungal market was valued at approximately USD 13 billion in 2022.
- Liposomal Amphotericin B accounts for about 25% of the antifungal market, estimated at USD 3.25 billion.
- The compound's market growth rate is projected at 5% annually through 2027 ([1]).
Key Competitors
- Fungizone (Amphotericin B deoxycholate): Older formulation, less expensive but higher toxicity.
- Ambisome (Liposomal Amphotericin B): Market leader for efficacy and safety.
- Other formulations: Newer agents such as rezafungin (2020s) and isavuconazole are expanding options.
Market Drivers
- Rising prevalence of invasive fungal infections.
- Increased use of immunosuppressive therapies and transplant procedures.
- Growing awareness of toxicity profiles and improved safety with liposomal formulations.
Market Challenges
- High treatment costs.
- Reimbursement variability.
- Emergence of newer antifungal agents with better ease-of-use profiles.
Price Projections
Current Pricing Landscape
- Average Wholesale Price (AWP): Approximately USD 18,000 to USD 22,000 per 50 mg vial (as of late 2022).
- Average Sale Price (ASP): Estimated at USD 12,000 to USD 16,000 per vial.
- Higher-dose vials and multi-dose vials tend to have proportional pricing increases.
Historical Price Trends
- Prices for liposomal Amphotericin B have increased at an average rate of 3.5% annually since 2010 ([2]).
- Price stabilization occurred around 2018, with recent slight increases due to supply chain factors.
Future Price Projections
- Prices are expected to stabilize or decline marginally over the next five years, considering biosimilar and generic entry. However, as augmentative pricing and supply chain dynamics evolve, prices may fluctuate:
| Year |
Estimated ASP per 50 mg vial (USD) |
Notes |
| 2023 |
14,000 – 16,000 |
Current market range |
| 2024 |
13,500 – 15,500 |
Slight decrease expected |
| 2025 |
13,000 – 15,000 |
Biosimilar competition increases |
| 2026 |
12,500 – 14,500 |
Market stabilization, slight decline |
| 2027 |
12,000 – 14,000 |
Possible price erosion |
Impact of Biosimilars
- Patent expiry anticipated around 2028 in the U.S. ([3]), with biosimilars potentially reducing prices by 20-30%.
- Entry of biosimilars may primarily affect procurement prices for hospitals and insurers, rather than consumer prices.
Reimbursement Dynamics
- CMS reimbursement rates for hospital-administered drugs are expected to constrict margins unless negotiated discounts are obtained.
- Variability among payers could influence net pricing strategies.
Conclusion
The market for liposomal Amphotericin B (NDC 00069-0335) remains considerable, driven by increasing clinical demand and incidence of fungal infections. Pricing is historically stable with gradual increases but is poised to decline following biosimilar entry. Price sensitivity varies across healthcare settings, with hospitals and insurers favoring price negotiations and formularies.
Key Takeaways
- The drug targets a growing market driven by immunocompromised patient populations.
- Current average prices per vial are USD 14,000–16,000.
- Prices are expected to decline modestly over the next five years, influenced by biosimilar entry.
- Revenue and market share will depend on safety profiles, clinical efficacy, and reimbursement policies.
- Patent exclusivity expected to lapse around 2028, opening price competition.
FAQs
1. What factors influence the price of liposomal Amphotericin B?
Clinical demand, patent status, manufacturing costs, competition from biosimilars, reimbursement policies, and supply chain factors.
2. When will biosimilars likely enter the U.S. market for this drug?
Patent expiration is anticipated around 2028, potentially leading to biosimilar availability soon after.
3. How does the cost of liposomal Amphotericin B compare to older formulations?
Liposomal formulations are approximately 2-3 times more expensive, reflecting improved safety and tolerability.
4. What are the main drivers for the increasing global demand?
Rise in invasive fungal infections, expanding immunocompromised patient base, and improved diagnosis.
5. How might hospital formulary decisions impact pricing?
Hospitals may negotiate discounts or select lower-cost alternatives, influencing net prices and market share distribution.
References
[1] MarketsandMarkets. (2022). Antifungal Drugs Market Report.
[2] U.S. Food and Drug Administration. (2022). Amphotericin B product approvals and pricing trends.
[3] NIH. (2023). Patent status and biosimilar development timelines for Amphotericin B.
